Pomerantz Law Firm Launches Class Action Against PepGen Inc. Amid Serious Allegations

Pomerantz Law Firm Files Class Action Against PepGen Inc.



On July 2, 2025, Pomerantz LLP, a prominent law firm known for its dedication to corporate litigation, announced the filing of a class action lawsuit against PepGen Inc. and certain of its officers. This legal action, registered in the United States District Court for the Eastern District of New York and listed under the docket number 25-cv-03221, aims to represent all individuals and entities, excluding the defendants, who purchased or acquired PepGen securities during the period from March 7, 2024, to March 3, 2025, inclusive.

The suit seeks damages for perceived violations of federal securities laws and aims to utilize protections outlined in Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as well as Rule 10b-5. Investors impacted by these allegations are encouraged to apply for the role of Lead Plaintiff before the deadline of August 8, 2025. More information and a copy of the complaint can be found on Pomerantz Law Firm's website.

Allegations Against PepGen Inc.


PepGen Inc. is a clinical-stage biotechnology company focused on developing oligonucleotide therapeutics for the treatment of severe neuromuscular and neurological disorders. The lead product candidate of the company, PGN-EDO51, is intended to treat Duchenne muscular dystrophy (DMD), a genetic condition that leads to progressive muscle degeneration due to a lack of dystrophin protein produced from the mutation of the dystrophin gene. The firm's approach aims to enable the production of a modified but functional dystrophin protein by targeting a specific area of the dystrophin transcript.

Unfortunately, the lawsuit claims that PepGen's management misled investors regarding the efficacy, safety, and commercial prospects of PGN-EDO51. Specifically, the allegations assert that throughout the specified Class Period, company officials misrepresented the success and regulatory approvals of their PGN-EDO51 clinical trials, particularly the CONNECT1 and CONNECT2 studies, which evaluated the drug's effectiveness in DMD patients.

Claims raised in the complaint include assertions that the defendants misrepresented the effectiveness of PGN-EDO51, failed to disclose significant safety concerns, and projected inflated expectations about the drug's clinical trials. It states that the CONNECT2 study was potentially dangerous, leading to a higher probability that the trials would be halted before reaching substantial conclusions. Rather than reassuring investors, the firm allegedly perpetuated a false narrative that led to an overestimated confidence in the company's drug and prospects.

In a specific incident reported on July 30, 2024, PepGen shared what it claimed to be successful preliminary data from the CONNECT1 trial. Still, subsequent analysis from financial experts noted that the results fell far below the company's expectations, ultimately leading to a significant drop in the stock price.

Impact and Consequences


Several other instances throughout the class period further exacerbated investor concerns. Following the unveiling of a clinical hold notice from the FDA on December 16, 2024, concerning potential risks involved in the CONNECT2 study, and subsequent updates revealing safety concerns observed in the CONNECT1 study, PepGen's stock faced relentless drop-offs. The sequence of events eventually culminated on March 4, 2025, when the company voluntarily suspended the CONNECT2 study to reassess the data from the ongoing CONNECT1 trial, which led to another decline in stock value.

These developments have sparked serious doubts about the company's standing in the biotechnology sector and its credibility among investors. Ultimately, on May 28, 2025, it was revealed that PGN-EDO51 had failed to meet its target dystrophin levels, resulting in PepGen's decision to discontinue its DMD programs altogether.

Future Steps


Pomerantz LLP aims to represent affected investors by seeking remedies for their losses due to the alleged misconduct of PepGen and its executives. The firm is recognized nationally for its efforts in securities class action litigation and has a long-standing history of advocating for the rights of investors against corporate malfeasance. Founded by Abraham L. Pomerantz, the firm has, over the years, recovered billions in damages for its clients, continuing to uphold the standards of justice and accountability in the investment arena.

As the litigation develops, investors who believe they have suffered losses related to PepGen's deceptive practices are invited to participate and gain insight into their rights and options. Interested parties can reach out to Danielle Peyton through the contact information provided for any inquiries or clarifications regarding the ongoing class action proceedings.

Topics Consumer Technology)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.